

Urgent Field Safety Notice

SBN-RDS-NPC-2026-004

RDS / Near Patient Care
Version 1

cobas® b 123 Sensor Cartridge: Measurement Deviations of Ionized Calcium at Extremely Low Concentrations (CiCa CRRT)

Product Name / GMMI / Device Identifier (UDI)	Product Name	GMMI	UDI
	cobas b 123 Sensor Cartridge BG/ISE	05170460001	04015630037674
	cobas b 123 Sensor Cartridge BG/ISE/Glu	05331781001	04015630038350
	cobas b 123 Sensor Cartridge BG/ISE/Glu/Lac	05170478001	04015630037681
Production Identifier (Lot No./Serial No.)	All		
SW Version	Not applicable		
Type of Action	Field Safety Corrective Action (FSCA)		

Dear Valued Customer,

Description of Situation

During routine reference testing on ionized calcium (iCa, Ca++) using the cobas b 123 POC system, a concentration dependent offset against the target values was found. This offset may occur at extremely low concentrations, i.e. ≤ 0.5 mmol/L. The observed bias originates from the measurement value calculation on the cobas b 123 POC system. Investigations with certified reference material have shown that the cobas b 123 is relatively well aligned in the physiological range against certified material target values. It deviates only at extremely low concentration ranges (≤ 0.5 mmol/L) and reaches its maximum deviation around 0.3 mmol/L, focusing on measurements within the process of Citrate-Calcium Continuous Renal Replacement Therapy (CiCa CRRT).

cobas® b 123 Sensor Cartridge: Measurement Deviations of Ionized Calcium at Extremely Low Concentrations (CiCa CRRT)

This issue is not likely to result in serious adverse health events for users of the device or even medically reversible/transient adverse health consequences for the overall population using the device.

However, there is a reasonable probability of medically reversible/transient adverse health consequences for the population at greatest risk (those on Continuous Renal Replacement Therapy with local Citrate-Calcium Anticoagulation (CRRT with CiCa)).

The error would not change the need for iCa infusion but could affect dosage, flow rate, and CRRT settings. It is likely to prompt repeat measurement due to limited plausibility. Minor treatment delay or transient overtreatment might occur, potentially causing overcorrection of iCa and reversible/transient adverse health events. Severe incremental harm is unlikely because regional citrate filtration is performed under strict protocols with close monitoring due to known risks (metabolic disturbances and electrolyte imbalances).

Actions taken by Roche Diagnostics (if applicable)

A Corrective and Preventive Action (CAPA) investigation has been initiated. As the root cause has been identified, an appropriate corrective measure has been determined and will be verified for effectiveness. The measurement bias will be corrected by implementing an updated correction factor on the chip of the sensor cartridge. The implementation and roll out of the change to the field is planned for Q4 2026 and will be communicated accordingly.

cobas® b 123 Sensor Cartridge: Measurement Deviations of Ionized Calcium at Extremely Low Concentrations (CiCa CRRT)

Actions to be taken by the customer/user

- *iCa* results below 0.5 mMol/L might still be used to trigger an action when using the cobas b 123 POC system for testing patients' blood post filtration undergoing with CRRT with *CiCa*, but the follow-up implications change: the end users must treat the patient as being in an "unsteady state," increase monitoring frequency, and shift the focus to systemic *iCa* to verify the true impact of the therapy change as *iCa* systemic results are fully reliable and represent the primary guide post-adjustment (safely monitoring and confirmation of the effects on therapy changes). Furthermore, refer to standard reference protocols for detailed variations, such as the [Citrates clinical guideline from CRRT Online](#) or the [NCBI Review on Citrate Anticoagulation](#).
- No general recommendations with respect to the review of previous results can be given for using the cobas b 123 POC system. Customers should follow their standard laboratory operating procedures. Any specific questions raised by the users should be addressed individually, considering all relevant clinical information.

Communication of this Field Safety Notice (if appropriate)

<If the recipient needs to forward the FSN to additional organizations/individuals then one or more of the following statements may be included:

This notice must be passed on to all those who need to be aware within your organization or to any organization/individual where the potentially affected devices have been distributed/supplied. (If appropriate).

Please transfer this notice to other organizations/individuals on which this action has an impact. (If appropriate).

Please maintain awareness of this notice and resulting action for an appropriate period to ensure the effectiveness of the corrective action. (If appropriate).>

The following statement is mandatory in FSNs for EEA countries but is not required for the rest of the World:

Include if applicable: The undersigned confirms that this notice has been notified to the appropriate Regulatory Agency.

We apologize for any inconvenience this may cause and hope for your understanding and your support.

cobas[®] b 123 Sensor Cartridge: Measurement Deviations of Ionized Calcium at Extremely Low Concentrations (CiCa CRRT)

<closing salutations>,

Contact Details

To be completed locally:

Name

Title

Company Name

Address

Tel. +xx-xxx-xxxx xxxx

Email name@roche.com

Roche Diagnostics GmbH - SRN: DE-MF-000006260 (legal manufacturer)